Corporate venture firms are a well-established presence on the biotech funding scene, with the likes of Novartis and Glaxosmithkine’s SR One among the most active investors in the sector. However, the past few years have seen some different names crop up more and more: Pfizer, Celgene and Roche have noticeably stepped up their financing activity, a new analysis by EP Vantage finds.